{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:38:31Z","timestamp":1761885511381,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.acuroe.2023.01.008","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T19:50:12Z","timestamp":1677268212000},"page":"395-397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["An aid to a better understanding of the definitions of BCG failure provided by the European Urology Association"],"prefix":"10.1016","volume":"47","author":[{"given":"J. Huguet","family":"P\u00e9rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. Rodr\u00edguez","family":"Faba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Gaya Sopena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Palou Redorta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Breda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2023.01.008_bib0005","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Mantainance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0010","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces de risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomiced clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0015","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"Van den Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Scherier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \u201cprimary\u201d and \u201csecondary\u201d muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2005.03.021","article-title":"Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor","volume":"48","author":"Huguet","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0210-4806(10)70011-5","article-title":"Radical cystectomy in patients with non-muscle-invasive bladder cancer who fail BCG therapy","volume":"34","author":"Huguet","year":"2010","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0040","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","article-title":"Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer","volume":"27","author":"Lerner","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0050","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial b\u00f1adder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0055","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy","volume":"71","author":"Gallager","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0060","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3 month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0065","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0070","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bju.15567","article-title":"Contemporary outcomes of bladder carcinoma in situ treated with adecuate bacille Calmette-Guerin inmunotherapy","volume":"129","author":"Subiela","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0075","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-5347(05)67973-6","article-title":"Recurrence progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations","volume":"163","author":"Lebret","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2023.01.008_bib0080","unstructured":"EAU Guidelines in non-muscle-invasive bladder cancer v 2022 (consultado en noviembre 2022). Disponible en https:uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer\/."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578623000173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578623000173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:16:24Z","timestamp":1761880584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578623000173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2173578623000173"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2023.01.008","relation":{},"ISSN":["2173-5786"],"issn-type":[{"type":"print","value":"2173-5786"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An aid to a better understanding of the definitions of BCG failure provided by the European Urology Association","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2023.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2023.01.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}